Mary Ann Cameron, MD
Nephrology · Tulsa, OKNPI 1619924677
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 25.5% of the total.
Across 242 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$628
- Travere Therapeutics, Inc.$493
- Daiichi Sankyo Inc.$401
- Novartis$360
- Bayer$267
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,231100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 52 | $1,335 |
| Amgen(2 entities) | 37 | $628 |
| Travere Therapeutics, Inc. | 24 | $493 |
| Daiichi Sankyo Inc. | 19 | $401 |
| Novartis | 17 | $360 |
| Bayer | 13 | $267 |
| Otsuka America Pharmaceutical, Inc. | 11 | $203 |
| Vifor Pharma, Inc. | 9 | $183 |
| Mallinckrodt Hospital Products Inc. | 7 | $159 |
| Johnson & Johnson | 3 | $152 |
| OPKO Pharmaceuticals, LLC | 8 | $137 |
| GSK | 5 | $89 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $76 |
| Genentech USA, Inc. | 4 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $62 |
| Boehringer Ingelheim | 3 | $59 |
| Veloxis Pharmaceuticals, Inc. | 2 | $57 |
| Calliditas Therapeutics US Inc. | 2 | $54 |
| Cycle Pharmaceuticals Inc | 2 | $52 |
| Akebia Therapeutics Inc | 3 | $47 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Novo Nordisk | 2 | $41 |
| Pharmacosmos Therapeutics Inc. | 1 | $33 |
| Shield Therapeutics Inc | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Angiodynamics, Inc. | 1 | $24 |
| Biogen | 1 | $24 |
| Strongbridge US Inc. | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,235 in reported general payments places this provider in the 70th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $251,027 |
| FarxigaDapagliflozin Propanediol | 285 | $208,795 |
| Thiola EcTiopronin | 12 | $127,226 |
| JardianceEmpagliflozin | 103 | $76,247 |
| KerendiaFinerenone | 56 | $48,295 |
| Losartan Potassium | 287 | $2,903 |
| Potassium Citrate ErPotassium Citrate | 40 | $2,685 |
| Paricalcitol | 14 | $2,545 |
| Metoprolol Succinate | 127 | $2,164 |
| Amlodipine Besylate | 323 | $1,902 |
| Allopurinol | 66 | $1,594 |
| Hydralazine Hcl | 74 | $1,329 |
| Nebivolol Hcl | 19 | $1,224 |
| Calcitriol | 64 | $908 |
| Estradiol | 12 | $843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $203 | $251,02713 claims |
| AstraZenecaFarxiga | $1,335 | $208,795285 claims |
| Boehringer IngelheimJardiance | $59 | $76,247103 claims |
| BayerKerendia | $267 | $48,29556 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $44 | $33831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.